Mantle Cell Lymphoma
Feature
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
From the Journals
Meta-analysis supports rituximab maintenance in MCL
Rituximab maintenance therapy prolonged progression-free survival. Risk of grade 3 or 4 neutropenia was increased, but risk of infection was not...
From the Journals
PET/CT accurately predicts MCL stage
The promising results suggest bone marrow involvement could be assessed without a biopsy.
From the Journals
Late mortality risk after childhood BMT is substantial, persistent
Patients who undergo blood or marrow transplant as children need “lifelong follow-up care.”
From the Journals
New guideline for managing MCL
From the Journals
Bortezomib plus vorinostat shows modest response in MCL
The phase 2 trial looked at the combination in mantle cell lymphoma and diffuse large B-cell lymphoma patients.
From the Journals
British good practice paper offers MCL diagnosis pearls
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
From the Journals
Overcoming TP53 mutation proves difficult in MCL
A new study shows disappointing results for the addition of lenalidomide to chemoimmunotherapy regimens.
From the Journals
Adding bortezomib does not improve MCL outcomes
The addition of bortezomib is a bust in patients with newly diagnosed mantle cell lymphoma.
From the Journals
In young MCL patients, optimal treatment may vary
Novel agents have produced mixed results in younger mantle cell lymphoma patients.
From the Journals
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.